Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on November 27, 2012. The filing reports on a material definitive agreement and other events involving Teva Pharmaceutical Industries Limited regarding the development of the anti-cancer compound RX-3117. Note: The request metadata lists "Opus Genetics, Inc.", but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Agreements
- Research Funding: Teva agreed to provide an additional $926,000 in research funding for the development of RX-3117.
- Stock Purchase: Teva agreed to exercise an option to purchase $750,000 of Rexahn's common stock.
- Purchase Price: The stock purchase price is set at 120% of the closing market share price on or around December 7, 2012.
- Regulatory Rights: Teva was granted the right to file the Investigational New Drug (IND) application for RX-3117 with the FDA.
Material Changes
The filing details a Second Amendment to the Research and Exclusive License Option Agreement (RELO Agreement) originally dated June 26, 2009. This amendment modifies the scope of work and funding for RX-3117. Additionally, it marks the execution of the third and final closing under the Securities Purchase Agreement between the two parties.
Outlook, Risks, and Management Commentary
- Development Progress: The agreement facilitates additional R&D work by Teva on behalf of Rexahn and enables the filing of the IND application, a critical step in the drug approval process.
- Transaction Structure: The stock purchase is exempt from registration requirements under Section 4(2) of the Securities Act of 1933 as a transaction with an accredited investor.
- Future Rights: Rexahn granted Teva piggyback registration rights regarding the shares purchased, which Teva may exercise in the future.
- Financial Data: The filing text does not provide clear values for overall revenue, profit, cash flow, margins, debt, or liquidity for the company.
Investor Verification Checklist
- Verify the closing date and actual share price for the $750,000 stock purchase expected around December 7, 2012.
- Confirm the status of the IND application filing for RX-3117 with the FDA.
- Review the full text of Exhibit 10.1 (Amendment No. 2) for specific milestones tied to the $926,000 funding.
- Check subsequent filings for the issuance of shares and any impact on Rexahn's capitalization.